New hope for Tough-to-Treat pancreatic cancer?
NCT ID NCT07240766
Summary
This study is testing a new combination of drugs for people with a specific type of pancreatic cancer that is difficult to remove with surgery. It aims to see if adding the experimental drug HRS-4642 to standard treatments can better control the cancer and make surgery possible. The study will enroll 40 adults with borderline resectable pancreatic cancer that has a specific genetic change called KRAS G12D.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Zhejiang University Schlool of Medicine
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
the First Affiliated Hospital of Zhejiang University, School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.